Colony Group LLC Halozyme Therapeutics, Inc. Transaction History

Colony Group LLC

$6.66 Billion
Q3 2023

A detailed history of Colony Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Colony Group LLC holds 80,387 shares of HALO stock, worth $3.68 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

80,387

Previous 80,382 0.01%

Holding current value

$3.68 Million

Previous $2.9 Million 5.93%

% of portfolio

0.05%

Previous 0.04%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $182 - $220	5 Added 0.01%	80,387 $3.07 Million
Q2 2023 Aug 15, 2023	SELL	$30.28 - $38.74 $3,149 - $4,028	-104 Reduced 0.13%	80,382 $2.9 Million
Q1 2023 May 16, 2023	SELL	$32.86 - $55.7 $35,883 - $60,824	-1,092 Reduced 1.34%	80,486 $3.07 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $62,293 - $92,429	1,555 Added 1.94%	81,578 $4.64 Million
Q3 2022 Nov 15, 2022	SELL	$38.53 - $51.78 $49,780 - $66,899	-1,292 Reduced 1.59%	80,023 $3.16 Million
Q2 2022 Aug 16, 2022	BUY	$37.35 - $48.3 $19,085 - $24,681	511 Added 0.63%	81,315 $3.58 Million
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $27,462 - $35,270	859 Added 1.07%	80,804 $3.22 Million
Q4 2021 Feb 15, 2022	BUY	$31.82 - $40.75 $184,142 - $235,820	5,787 Added 7.8%	79,945 $3.22 Million
Q3 2021 Nov 17, 2021	BUY	$38.47 - $46.42 $27,429 - $33,097	713 Added 0.97%	74,158 $3.02 Million
Q2 2021 Aug 18, 2021	SELL	$38.84 - $51.31 $4,000 - $5,284	-103 Reduced 0.14%	73,445 $3.34 Million
Q1 2021 May 21, 2021	SELL	$39.51 - $51.45 $258,750 - $336,946	-6,549 Reduced 8.18%	73,548 $3.07 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $27,461 - $46,411	-1,064 Reduced 1.31%	80,097 $3.42 Million
Q3 2020 Nov 17, 2020	SELL	$25.74 - $29.63 $1.04 Million - $1.2 Million	-40,334 Reduced 33.2%	81,161 $2.13 Million
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $1,738 - $2,868	107 Added 0.09%	121,495 $3.26 Million
Q1 2020 May 18, 2020	BUY	$13.9 - $21.83 $701,505 - $1.1 Million	50,468 Added 71.16%	121,388 $2.18 Million
Q4 2019 Feb 18, 2020	BUY	$14.93 - $19.53 $9,853 - $12,889	660 Added 0.94%	70,920 $1.26 Million
Q3 2019 Nov 26, 2019	SELL	$15.2 - $17.69 $3,496 - $4,068	-230 Reduced 0.33%	70,260 $1.09 Million
Q2 2019 Aug 19, 2019	BUY	$14.75 - $17.26 $16,151 - $18,899	1,095 Added 1.58%	70,490 $1.21 Million
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $394,920 - $498,041	28,330 Added 68.99%	69,395 $1.12 Million
Q4 2018 Feb 15, 2019	SELL	$13.33 - $18.66 $417,962 - $585,084	-31,355 Reduced 43.3%	41,065 $601,000
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $3,669 - $4,050	-220 Reduced 0.3%	72,420 $1.32 Million
Q2 2018 Aug 15, 2018	BUY	$16.87 - $20.3 $1.23 Million - $1.47 Million	72,640 New	72,640 $1.23 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.37B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Colony Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Colony Group LLC with notifications on news.

Account